Frank L. Douglas, PhD, MD, is president and CEO of Austen BioInnovation Institute, (Akron, Ohio), Senior fellow of the Ewing Marion Kauffman Foundation, Senikor partner emeritus of PureTech Ventures (Boston, MA), and the founder and first executive director of the MIT Center for Biomedical Innovation. At MIT, he was the Professor of the Practice in the MIT Sloan School of Management and also held appointments in the departments of biology, biological engineering, and the Harvard-MIT Division of Health Sciences and Technology. Dr. Douglas was formerly executive vice president, chief scientific officer, and a member of the board of management of Aventis, where he headed drug innovation and approval, with global responsibilities for research, development, and regulatory and marketing support. A leader in innovation in pharmaceutical research and development, Dr. Douglas serves on multiple boards of directors, most recently joining that of the Multiple Myeloma Research Foundation. Dr. Douglas is the recipient of the 2007 Black History Makers Award and has been honored twice as the Global Pharmaceutical R&D Director of the Year. He has also received the Medal of Honor and an Honorary Professorship from the Johann Wolfgang von Goethe University, Frankfurt, Germany. Dr. Douglas holds a PhD in physical chemistry and a MD from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health.